Joshua Riggs compensation by year
Insight Molecular Diagnostics Summary Compensation Table · all 4 fiscal years held| Component | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Salary | $242,028 | $339,846 | $385,018 | $472,293 |
| Bonus | $94,801 | $117,000 | $166,400 | $184,675 |
| Stock awards | $0 | $0 | $0 | $599,999 |
| Option awards | $140,913 | $220,284 | $209,709 | $1,332,000 |
| Non-equity incentive | $0 | $0 | $0 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 |
| All other | $36,368 | $47,780 | $24,950 | $5,819 |
| Total | $514,110 | $724,910 | $786,077 | $2,594,786 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Insight Molecular Diagnostics Inc. DEF 14A filed April 30, 2026, accession 0001493152-26-020502, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Insight Molecular Diagnostics Inc. filed document, accession 0001493152-26-020502. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 188,679 | $599,999 | — |
| Option | 4,291 | — | $9.26 |
| Option | 322 | — | $7.80 |
| Option | 6,556 | — | $4.26 |
| Option | 54,375 | — | $2.76 |
| Option | 400,000 | — | $3.33 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Insight Molecular Diagnostics Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insight Molecular Diagnostics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Joshua Riggs · this page | President and Chief Executive Officer | $2,594,786 |
| Andrea James | Chief Financial Officer | $1,679,126 |
| James Liu | VP of Accounting, Controller, Treasurer & Principal Accounting Officer | $454,990 |
Board service
Insight Molecular Diagnostics board · FY2023–FY2025How this board is paid
Company policy: Insight Molecular Diagnostics pays directors a $85,427 cash retainer and $106,400 in RSUs. As stated in Insight Molecular Diagnostics's FY2025 proxy.
The full Insight Molecular Diagnostics compensation record
free company briefThis page is one person within Insight Molecular Diagnostics's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Insight Molecular Diagnostics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Insight Molecular Diagnostics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order IMDX
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.